Eli Lilly (LLY) Stock: Foundayo Outpaces Novos Ozempic in Latest Diabetes Data
Key TakeawaysEli Lilly claims Foundayo demonstrates superior performance compared to Novo Nordisks oral Ozempic in type 2 diabetes treatment.The 17.2 mg dose of Foundayo achieved up to 2% greater weight reduction than the 25 mg Ozempic pill.Novo Nordisks high-dose oral Ozempic has not received US approval for type 2 diabetes; FDA approval is anticipated by late 2026.Eli Lilly also published data indicating Zepbound‘s higher doses surpass Novo’s Wegovy HD in weight management.The 15 mg dose of Zepbound produced approximately 5% additional weight loss compared to Wegovy HD. Eli Lilly has taken an aggressive stance in the competitive diabetes and obesity drug market. The pharmaceutical giant unveiled fresh clinical data this week positioning its medications as superior alternatives to Novo Nordisks offerings. Eli Lilly and Company, LLY The announcement came Tuesday when Lilly declared that Foundayo demonstrates stronger performance than Novos oral Ozempic formulation in treating adults with type 2 diabetes. This assertion stems from an indirect statistical comparison rather than a direct clinical trial. The pharmaceutical company analyzed results from two distinct late-stage clinical trials to draw its conclusions. Researchers examined outcomes between Foundayo‘s 17.2 mg formulation and Novo’s 25 mg oral semaglutide tablet. Discover more Fintech investment reports Bitcoin investment guide News The findings revealed that Foundayo produced









